Jay Birnbaum Net Worth

Jay Birnbaum biography

Dr. Jay E. Birnbaum Ph.D. is Independent Director of the Company. Dr. Birnbaum is a pharmacologist and since 1999, has been a consultant to pharmaceutical companies in his area of expertise. He previously served as Vice President of Global Project Management at Novartis/Sandoz Pharmaceuticals Corporation, where he was also responsible for the strategic planning and development of the company’s dermatology portfolio. Dr. Birnbaum was a co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals (which was acquired by Allergan), and a member of the board of directors of Excaliard Pharmaceuticals (which was acquired by Pfizer). Dr. Birnbaum is a co-founder and member of the Board of Directors of Hallux, Inc., a co-founder and Executive Vice President of Lipido Pharmaceuticals, Inc., and serves on the scientific advisory board of several companies.

How old is Jay Birnbaum?

Jay Birnbaum is 75, he's been the Independent Director of Sonoma Pharmaceuticals since 2007. There are no older and 10 younger executives at Sonoma Pharmaceuticals.

What's Jay Birnbaum's mailing address?

Jay's mailing address filed with the SEC is C/O SONOMA PHARMACEUTICALS, INC., 5445 CONESTOGA COURT, SUITE 150, BOULDER, CO, 80301.

Insiders trading at Sonoma Pharmaceuticals

Over the last 8 years, insiders at Sonoma Pharmaceuticals have traded over $0 worth of Sonoma Pharmaceuticals stock and bought 25,155 units worth $125,359 . The most active insiders traders include Frederick J Sandford, Sharon Barbari a Robert E Miller. On average, Sonoma Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of $4,840. The most recent stock trade was executed by Robert E Miller on 12 March 2018, trading 2,400 units of SNOA stock currently worth $9,744.

What does Sonoma Pharmaceuticals do?

sonoma pharmaceuticals, inc., develops and produces stabilized hypochlorous acid (hocl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the united states and internationally. the company offers epicyn, an antimicrobial facial cleanser; levicyn, a hypochlorous acid (hocl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; sebuderm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and ceramax, a lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as loyon for the management of skin scal

Sonoma Pharmaceuticals executives and stock owners

Sonoma Pharmaceuticals executives and other stock owners filed with the SEC include:

• Bruce Thornton,
  Chief Operating Officer, Secretary
• Bruce Thornton,
  COO & Corp. Sec.
• Amy M. Trombly,
  CEO & Pres
• Amy Trombly,
  Chief Executive Officer
• Jerome Dvonch,
  Chief Financial Officer
• Philippe Weigerstorfer,
  Independent Director
• Jay Birnbaum,
  Independent Director
• Sharon Barbari,
  Independent Director
• Jerry McLaughlin,
  Lead Independent Director
• Jerry Dvonch,
  Chief Financial Officer
• Victoria Covel,
  Assistant Controller
• Dr. Robert Northey,
  Exec. VP of R&D
• Russell Joseph Harrison,
  Director
• John Mclaughlin,
  Director
• Marc Umscheid,
  Chief Strategy/Mkt Officer
• Robert Grant Edwards,
  Chief Financial Officer
• Poggetto John Dal,
  Controller
• Robert Allen Northey,
  Exec. VP of Res & Development
• James J Schutz,
  
• Robert E Miller,
  
• Frederick J Sandford,
  CEO and Interim CFO
• Chad Norman White,
  Chief Financial Officer
• Jerome J Dvonch,
  Chief Financial Officer